Guardant Health, Inc.

GH · Nasdaq · ·

Vergleichen

154,85 $+0,1 %Schluss 12. Nov.

Zahlen bis 30. September 2026, aus dem 10-Q vom 5. November 2026

1W: +2,6 %
1M: -5,0 %

Just reported

Q3 2026 results

From Guardant Health's results release of 5. November 2026; its quarterly report has since been filed.

Revenue
Actual
361M $
+36 % y/y
+7,8 % q/q
Guided
—
No guide given
EPS, GAAP
Actual
-0,93 $
Guided
—
No guide given
Operating income, GAAP
Actual
-132,8M $
Guided
—
No guide given

Company outlook

Full year 2026

Revenue1,36B $ – 1,37B $+39 % y/y Raised +1,1 %

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

Keep exploring

The themes Guardant Health is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

The theme it is part of

Kuratiert
Lab tools & diagnostics
Von InspectStocks · 20 companies
Instruments, supplies and testing services for labs, drugmakers and doctors.
Kurs, 1 Jahr
+21,6 %
Umsatz, 1 Jahr
+7,8 %
+14
A 8B 8C 2D 1F 1

Highest-graded in Diagnostics and Research

Graded A or B and worth $2B or more: A first, then the largest.

All 42 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

Vollständige Abschlüsse →

Gebaut aus den eigenen Einreichungen von Guardant Health, Inc. bei der US-Börsenaufsicht Securities and Exchange Commission (SEC). Die Zahlen sind wie berichtet, die Historie je Aktie auf die heutige Aktienbasis umgerechnet. Dies beschreibt ein Unternehmen — es ist keine Anlageberatung und keine Kauf- oder Verkaufsempfehlung.

Guardant Health, Inc.

Guardant Health, Inc.

Q3 2026 results

Revenue

EPS, GAAP